31 May 2024 - The EMA’s CHMP recommended 14 medicines for approval at its May 2024 meeting.

The CHMP recommended granting a marketing authorisation under exceptional circumstances for Adzynma (rADAMTS13) an enzyme replacement therapy indicated for the treatment of children and adult patients with congenital thrombotic thrombocytopenic purpura, a rare, life-threatening blood disorder characterised by blood clotting in small blood vessels throughout the body that can result in organ damage and premature death.

Read EMA press release